Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.71 |
| ▸ | MMP1 | P03956 | 6/20 | 0.71 |
| ▸ | MMP2 | P08253 | 6/20 | 0.71 |
| ▸ | MMP9 | P14780 | 6/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.64 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.64 |
| ▸ | EP300 | Q09472 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228591 | 1.00 | EGFR (0.71) | EGFRMMP1MMP2MMP9HDAC1 | |
| SCHEMBL2640602 | 0.90 | HDAC1 (0.66) | EGFRMMP1MMP2MMP9HDAC1 | |
| SCHEMBL7978520 | 0.89 | HDAC1 (0.64) | EGFRMMP1MMP2MMP9HDAC1 | |
| SCHEMBL1059639 | 0.88 | HDAC1 (0.63) | EGFRMMP1MMP2MMP9HDAC1 | |
| SCHEMBL1059642 | 0.88 | HDAC1 (0.63) | EGFRMMP1MMP2MMP9HDAC1 | |
| SCHEMBL4536422 | 0.88 | TRPA1 (0.68) | EGFRMMP1MMP2MMP9HDAC1 | |
| SCHEMBL4536420 | 0.88 | TRPA1 (0.68) | EGFRMMP1MMP2MMP9HDAC1 | |
| SCHEMBL13180844 | 0.88 | HDAC1 (0.74) | EGFRMMP1MMP2MMP9HDAC1 | |
| SCHEMBL8348482 | 0.88 | TRPA1 (0.68) | EGFRMMP1MMP2MMP9HDAC1 | |
| SCHEMBL28633277 | 0.88 | HDAC1 (0.63) | EGFRMMP1MMP2MMP9HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-2238103-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-7795315-B2 | N-(2-amino-phenyl)-amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20090203681-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
| WO-2009095324-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | SALL4, GLI2, GLI1 | EGFR 261/4885MMP1 4680/4885MMP2 2852/4885 |
| US-20090203681-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | MKI67, API5, BAD | EGFR 652/4885MMP1 376/4885MMP2 97/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | EGFR 3886/4885MMP1 881/4885MMP2 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.